NewsHK
Against a backdrop of clinical-stage dermatology companies recalibrating their platform strategies to reach nearer-term revenue, Azitra, Inc.
(NYSE American: AZTR) posted a second-quarter 2026 net loss of $3.3 million on August 12, widening from $2.9 million in the comparable period a year earlier.
The Branford, Connecticut company used the report to signal a deliberate pivot: first preclinical data from its ATR-COSF recombinant filaggrin program showed repeat-dose delivery into targeted skin layers and anti-wrinkle activity in ex vivo human skin, clearing the bar for a planned proof-of-concept cosmetic study set to begin in Q3 2026.
Reading the balance sheet Research and development spending held flat at $1.4 million for the quarter, matching the prior-year period, while general and administrative costs rose to $2.1 million from $1.5 million.
Keep reading